Skip to main content
Aelis Farma logo

Aelis Farma — Investor Relations & Filings

Ticker · AELIS ISIN · FR0014007ZB4 LEI · 8945008D5R6WV7EXRN47 PA Manufacturing
Open in API
Filings indexed 157 across all filing types
Latest filing 2023-08-28 Regulatory Filings
Country FR France
Listing PA AELIS

About Aelis Farma

https://www.aelisfarma.com

Aelis Farma is a clinical-stage biopharmaceutical company that discovers and develops treatments for brain and central nervous system (CNS) disorders. The company has created a new class of drugs called Signaling Specific inhibitors of the CB1 receptor (CB1-SSi). This proprietary mechanism is designed to selectively inhibit the pathological signaling of the CB1 receptor, which is implicated in various brain diseases, while preserving its normal physiological functions and avoiding adverse effects associated with previous CB1-targeting drugs. The company's lead drug candidate, AEF0117, is in development for the treatment of Cannabis Use Disorder (CUD). Its second candidate, AEF0217, is being investigated for the treatment of cognitive deficits, including those associated with Down syndrome.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and announces a specific, non-financial event: the CEO of Aelis Farma receiving an award from the European Behavioural Pharmacology Society (EBPS). It details the award, the CEO's presentation topic, and includes standard sections like 'About EBPS' and 'About Aelis Farma', concluding with contact information and forward-looking statements. This format is characteristic of a general corporate announcement or press release, not a formal regulatory filing like a 10-K, IR, or ER. Since the content is an announcement of an achievement/event rather than a financial report, management change, or capital action, the most appropriate general category for a non-standard, non-financial corporate announcement is 'Regulatory Filings' (RNS) as a fallback, although 'LTR' (Legal Proceedings Report) or 'MANG' (Board/Management Information) are clearly incorrect. Given the options, and that it is a general corporate communication, RNS is the best fit among the provided codes for a press release that doesn't fit a more specific category like DIV, CAP, or ER.
2023-08-28 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is explicitly titled 'Press release' and announces the company's participation in a scientific conference (Gordon Research Conference) and the presentation of research findings by the CEO. It contains standard press release elements like date, location, company boilerplate ('About AELIS FARMA'), and contact information, including a 'Disclaimer' and 'Forward-looking statements' section typical of such announcements. This format does not align with comprehensive financial reports (10-K, IR, ER), regulatory filings (RNS), or specific corporate actions (DIV, CAP). Since it is a general announcement of company activity and scientific progress, it best fits the general 'Regulatory Filings' category as a catch-all for non-standard, non-financial disclosures, or potentially 'LTR' if the context implied a regulatory update, but given the scientific focus, 'RNS' (Regulatory Filings/General Announcement) is the most appropriate fit among the provided options for a press release that isn't an earnings release or specific corporate action.
2023-07-20 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 98% confidence The document is titled 'Communiqué de presse' (Press Release) and announces the company's participation in a scientific conference (Gordon Research Conference) and the presentation of its research findings (AEF0217 for cognitive impairments). It details scientific progress and includes forward-looking statements ('Déclarations prospectives'). This content structure—announcing corporate/scientific news via a press release format—does not align with mandatory regulatory filings like 10-K, IR, or ER, nor does it fit specific categories like Director's Dealing (DIRS) or Dividend Notice (DIV). Since it is a general announcement of corporate activity/scientific progress that doesn't fit a more specific category (like IP for a formal investor presentation or CT for a call transcript), it best fits the general 'Regulatory Filings' fallback category (RNS) for miscellaneous corporate announcements, although 'Investor Presentation' (IP) could be considered if the content were more focused on investment strategy rather than scientific participation. Given the format is a standard press release announcing participation and research updates, RNS is the most appropriate general classification for non-standard announcements.
2023-07-20 French
Inside Information / Other news releases
Earnings Release Classification · 95% confidence The document is explicitly titled 'Press release' and announces a positive recommendation from the Data Safety Monitoring Board (DSMB) regarding a Phase 2b clinical study for a drug candidate (AEF0117). This type of announcement, detailing clinical trial progress, safety data review, and future expectations, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a press release focused on operational/clinical progress rather than a full financial report (10-K, IR) or a management discussion (MDA), the most appropriate classification among the provided options is 'Earnings Release' (ER), as these often include key operational highlights and clinical milestones alongside or instead of preliminary financial figures. It is not a transcript (CT), a formal regulatory filing like 10-K, or a specific management/board change announcement (MANG). Given the context of clinical trial updates being key investor news, ER is the best fit for a major operational press release. FY 2023
2023-07-05 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 97% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and announces a positive recommendation from the Data Safety Monitoring Board (DSMB) regarding a Phase 2b clinical trial for the drug AEF0117. This type of announcement, detailing key operational and clinical progress (especially positive safety/tolerance data from a trial milestone) but not providing the full periodic financial results (like a 10-K or IR), strongly aligns with an Earnings Release (ER) or a general operational update. Since it focuses on clinical trial progress and safety milestones rather than quarterly financial figures, it is best classified as an operational announcement. Given the options, 'ER' (Earnings Release) is often used broadly for significant operational updates in the biotech/pharma sector when a specific 'Clinical Update' code is unavailable, as it communicates key performance indicators (trial status/safety). However, since it is a press release announcing a specific clinical milestone, and not a formal financial report, 'RNS' (Regulatory Filings/General Regulatory Announcements) is a strong candidate if 'ER' is strictly for financial results. Given the context of financial reporting databases, press releases announcing major operational milestones often fall under 'ER' or 'RNS'. Since this is a major operational update (DSMB sign-off) and not a formal financial report, 'ER' is slightly more specific than the general 'RNS' fallback, although it is not strictly an earnings release. Let's re-evaluate based on the definitions. It is not 10-K, AR, IR, or MDA. It is a press release announcing a positive clinical development. This fits best under 'ER' (Earnings Release) as the closest category for a major, time-sensitive operational announcement, or 'RNS' as a general regulatory/company announcement. Given the focus on clinical progress, 'RNS' is the safest general classification for non-financial, non-governance, non-legal specific announcements, but 'ER' is often used for press releases announcing key operational milestones in this industry. I will lean towards 'ER' as it communicates a key performance indicator/milestone, similar to how earnings are communicated, but acknowledge the ambiguity. Upon final review, this is a press release about clinical trial progress, which is a core operational update. In many databases, these fall under the 'Earnings Release' umbrella if a dedicated 'Clinical Update' category is missing. I will select ER.
2023-07-05 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Capital/Financing Update Classification · 94% confidence The document is titled "Bilan semestriel du contrat de liquidité" (Semi-annual statement of the liquidity contract) and is dated July 4, 2023, reporting figures as of June 30, 2023. This document details the activity (purchases and sales of shares) under a liquidity agreement over the first half of the year (H1 2023). This type of periodic report concerning share trading activity, often related to market making or stabilization, is not explicitly covered by the main definitions like 10-K, ER, or IR. However, it is a specific financial/regulatory disclosure related to the company's stock management. Since it is a periodic report detailing financial/market operations (liquidity contract management), it is closest to a specialized financial update. Given the options, it does not fit well into standard financial reports (10-K, IR) or management disclosures (MDA). It is a specific regulatory/contractual disclosure. The closest fit among the provided codes for a periodic report detailing specific financial/market operations that isn't a standard earnings report or annual report is often categorized under general regulatory filings (RNS) or, if it relates to capital structure/share movement, potentially SHA or POS. Since this is a report on the *liquidity contract* activity, which involves transactions in the company's own shares, POS (Transaction in Own Shares) is a possibility, but POS usually refers to formal buyback programs. Given the nature of a 'Bilan semestriel' (Semi-annual report) that is not a full financial report (like IR or 10-K), and since it details transactions related to the company's stock, it is a specific disclosure. In the absence of a specific 'Liquidity Contract Report' code, and noting that it details transactions in the company's own shares, POS is the most relevant category describing the underlying activity, although it is a report *about* the activity rather than the transaction itself. Alternatively, RNS (Regulatory Filings) is a safe fallback. Given the detailed nature of the report (23k chars) and its specific focus on share transactions under a contract, I will classify it as POS, as it directly relates to transactions in own shares, even if it's a report on the contract managing those transactions. If it were purely an announcement of the report, it would be RPA, but this appears to be the report content itself.
2023-07-04 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.